For his research efforts to better understand the molecular pathways that are responsible for axonal degeneration in glaucoma, Richard Libby, PhD, was awarded the 2017 Shaffer Prize for Research during Thursday night’s Glaucoma 360 annual Gala.
Over the years, Glaucoma 360 has brought the concept of innovation in glaucoma to the forefront. This year’s meeting will surpass the Glaucoma Research Foundation’s (GRF) own “Horizons” by adding a few more “degrees” to its 360-degree concept.
A renowned ophthalmologist and an accomplished opera singer were the highlight of Thursday night’s Glaucoma 360 annual Gala, when the two were presented with the Glaucoma Research Foundation’s (GRF) highest honors—The Catalyst Award and Visionary Award.
Research. Industry. Philanthropy. These three facets—each with a unique purpose—will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.
The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
Device manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.